Improvement of Doxorubicin Efficacy Using Liposomal Anti-Polo-like Kinase 1 siRNA in Human Renal Cell Carcinomas
Author:
Affiliation:
1. Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo 060-0812, Japan
Funder
Japan Society for the Promotion of Science
Publisher
American Chemical Society (ACS)
Subject
Drug Discovery,Pharmaceutical Science,Molecular Medicine
Link
https://pubs.acs.org/doi/pdf/10.1021/mp500245z
Reference29 articles.
1. Novel Therapies for Metastatic Renal Cell Carcinoma: Efforts to Expand beyond the VEGF/mTOR Signaling Paradigm
2. Immunotherapeutic strategies in kidney cancer—when TKIs are not enough
3. Recent advances in molecular targeted therapy for metastatic renal cell carcinoma
4. Delivery materials for siRNA therapeutics
5. Knocking down barriers: advances in siRNA delivery
Cited by 44 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Effective strategies to enhance the diagnosis and treatment of RCC: The application of biocompatible materials;Materials Today Bio;2024-08
2. Reprogramming tendon healing: a guide to novel molecular tools;Frontiers in Bioengineering and Biotechnology;2024-05-09
3. The application strategy of liposomes in organ targeting therapy;WIREs Nanomedicine and Nanobiotechnology;2024-03
4. Nanomedicine for renal cell carcinoma: imaging, treatment and beyond;Journal of Nanobiotechnology;2023-01-03
5. Advanced Nanomaterials for the Diagnosis and Treatment of Renal Cell Carcinoma;Advanced NanoBiomed Research;2022-12-21
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3